This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mandic, R. Articles by Werner, J. A. Search for Related Content PubMed PubMed Citation Articles by Mandic, R. Articles by Werner, J. A.

Reduced Cisplatin Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines Correlates with Mutations Affecting the COOH-Terminal Nuclear Localization Signal of p53

Authors' Affiliations: ¹ Department of Otolaryngology/Head and Neck Surgery, University of Marburg, Marburg, Germany; ² Institute of Cancer Research, Medical University Vienna, Vienna, Austria; ³ Department of Physical Biochemistry, Max Planck Institute of Molecular Physiology, Dortmund, Germany; ⁴ Department of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan; and ⁵ Department of Otolaryngology/Head and Neck Surgery, University of Turku, Turku, Finland

Requests for reprints: Robert Mandic, Department of Otolaryngology/Head and Neck Surgery, University of Marburg, Deutschhausstrasse 3, D-35037 Marburg, Germany. Phone: 49-6421-2862420; Fax: 49-6421-2862421; E-mail: mandic{at}med.uni-marburg.de.

Purpose: Head and neck squamous cell carcinomas (HNSCC) are the most frequent malignancies of the upper aerodigestive tract. Cisplatin resistance is a major problem in the treatment of a large number of HNSCC cancer patients. In this study, nine randomly selected HNSCC cell lines were investigated regarding expression, presence of mutations, nucleocytoplasmic distribution of p53, and sensitivity to cisplatin.

Experimental Design: Protein expression was evaluated by Western blot analysis. The whole open reading frame of p53 was determined by reverse transcription-PCR sequencing. Nucleocytoplasmic distribution was evaluated by confocal laser scanning microscopy. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide viability assay was used to test for cisplatin sensitivity.

Results: p53 mutations were found in all nine investigated HNSCC cell lines. Nuclear p53 signal was detected in six cell lines, whereas three cell lines exhibited total loss of nuclear p53 signal. Nuclear signal depended on the presence or absence of the COOH-terminal nuclear localization signal in p53. Cisplatin sensitivity was highly reduced in the group with loss of nuclear p53 signal compared with those with detectable nuclear signal. Transfection of wild-type and mutant p53 into a rat embryonic cell system showed highly reduced activity of the nuclear localization signal mutant p53 protein.

Conclusion: Taken together, these data suggest that "loss of nuclear p53 signal" correlates with cisplatin resistance in HNSCC. If these results can be validated on a larger number of tumor samples, including fresh tumor tissues, it potentially could help in sparing a subgroup of HNSCC patients the side effects associated with unnecessary chemotherapy by identifying cisplatin nonresponders before chemotherapy induction.

This article has been cited by other articles:

				S. Bhana, A. Hewer, D. H. Phillips, and D. R. Lloyd p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells Mutagenesis, March 1, 2008; 23(2): 131 - 136. [Abstract] [Full Text] [PDF]

				S. Bhana and D. R. Lloyd The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts Mutagenesis, January 1, 2008; 23(1): 43 - 50. [Abstract] [Full Text] [PDF]